+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cutaneous T-Cell Lymphoma - Pipeline Insight, 2021

  • ID: 4989147
  • Clinical Trials
  • July 2021
  • Region: Global
  • 100 pages
  • DelveInsight

FEATURED COMPANIES

  • 4SC AG
  • Elorac
  • Innate Pharma
  • Medc Biopharma
  • Soligenix
  • VidacPharma
  • MORE
This Cutaneous T-cell Lymphoma - Pipeline Insight, 2021 provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Cutaneous T-cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Cutaneous T-cell Lymphoma Understanding


Cutaneous T-cell Lymphoma: Overview


Cutaneous T cell lymphomas (CTCLs) are a heterogeneous group of extranodal non-Hodgkin's lymphomas that are characterized by a cutaneous infiltration of malignant monoclonal T lymphocytes. In cutaneous T-cell lymphoma, the T cells develop abnormalities that make them attack the skin. Cutaneous T-cell lymphoma can cause rash-like skin redness, slightly raised or scaly round patches on the skin, and, sometimes, skin tumors. The diagnosis of CTCLs is difficult at early stages because of the presence of multiple clinical presentations and lack of definitive diagnostic criteria. The diagnosis is based upon a thorough clinical evaluation, detection of certain symptoms and physical findings, a detailed patient history, and a variety of specialized tests. The risk of developing this rare cancer increases with age. Most people are diagnosed when they are in their 50s or older. Biopsies typically involve surgical removal and microscopic examination (i.e., histologic) of small samples of tissue cells gathered from CTCL skin lesions. The most common type and classic presentation of CTCL is known as mycosis fungoides and usually progresses slowly over many years. Treatment options may include: Skin creams and ointments, Light therapy (phototherapy), Radiation therapy, Medications, Exposing blood cells to light, and Bone marrow transplant.

Cutaneous T-cell Lymphoma - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cutaneous T-cell Lymphoma pipeline landscape is provided which includes the disease overview and Cutaneous T-cell Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Cutaneous T-cell Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cutaneous T-cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights


The companies and academics are working to assess challenges and seek opportunities that could influence Cutaneous T-cell Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Cutaneous T-cell Lymphoma.

Cutaneous T-cell Lymphoma Emerging Drugs Chapters


This segment of the Cutaneous T-cell Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cutaneous T-cell Lymphoma Emerging Drugs


Naloxone Hydrochloride: Elorac

Naloxone lotion is an investigational opiate antagonist designed to relieve pruritus associated with CTCL. The drug is currently in Phase III clinical evaluation for the treatment of cutaneous T-cell lymphoma. Elorac received Orphan Drug Designation for naloxone hydrochloride lotion from both FDA and the European Medicines Agency. Elorac also has Fast Track designation from FDA for this novel investigational new drug.

Cobomarsen: Viridian Therapeutics

Cobomarsen is an inhibitor of microRNA-155. microRNA-155 is believed to play an important role in the proliferation and survival of malignant cancer cells in certain types of blood cancer. The drug is currently in Phase II clinical evaluation for the treatment of Cutaneous T-cell Lymphoma (CTCL). On 23rd July 2020, miRagen Therapeutics (now Viridian Therapeutics) announced that the Food & Drug Administration (FDA) has granted orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma.

Cutaneous T-cell Lymphoma: Therapeutic Assessment


This segment of the report provides insights about the different Cutaneous T-cell Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:


Major Players in Cutaneous T-cell Lymphoma


There are approx. 25+ key companies which are developing the therapies for Cutaneous T-cell Lymphoma. The companies which have their Cutaneous T-cell Lymphoma drug candidates in the most advanced stage, i.e. Phase III include, Elorac.

Phases


This report covers around 25+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Cutaneous T-cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cutaneous T-cell Lymphoma: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cutaneous T-cell Lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cutaneous T-cell Lymphoma drugs.

Cutaneous T-cell Lymphoma Report Insights

  • Cutaneous T-cell Lymphoma Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Cutaneous T-cell Lymphoma Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Cutaneous T-cell Lymphoma drugs?
  • How many Cutaneous T-cell Lymphoma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cutaneous T-cell Lymphoma?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cutaneous T-cell Lymphoma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Cutaneous T-cell Lymphoma and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Soligenix
  • Elorac
  • 4SC AG
  • Merck Sharp & Dohme Corp.
  • Innate Pharma
  • Viridian Therapeutics
  • Sorrento Therapeutics
  • Bio-Path Holdings, Inc.
  • Legend Biotech USA Inc.
  • Genzada Pharmaceuticals
  • VidacPharma
  • Medc Biopharma

Key Products

  • SGX 301
  • Naloxone Hydrochloride
  • Resminostat
  • Letermovir
  • IPH4102
  • Cobomarsen
  • Sofusa anti-PD1
  • L-Bcl-2 antisense oligonucleotide
  • LB1901
  • GZ17-6.02
  • VDA-1102
  • MDC 2021


This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 4SC AG
  • Elorac
  • Innate Pharma
  • Medc Biopharma
  • Soligenix
  • VidacPharma
  • MORE
Introduction

Executive Summary

Cutaneous T-cell Lymphoma: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Cutaneous T-cell Lymphoma - Analytical Perspective

In-depth Commercial Assessment
  • Cutaneous T-cell Lymphoma companies' collaborations, Licensing, Acquisition -Deal Value Trends
Cutaneous T-cell Lymphoma Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Naloxone Hydrochloride: Elorac
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Cobomarsen: Viridian Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
Sofusa anti-PD1: Sorrento Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical and Discovery Stage Products
  • Comparative Analysis
VDA-1102: VidacPharma
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Cutaneous T-cell Lymphoma Key Companies

Cutaneous T-cell Lymphoma Key Products

Cutaneous T-cell Lymphoma- Unmet Needs

Cutaneous T-cell Lymphoma- Market Drivers and Barriers

Cutaneous T-cell Lymphoma- Future Perspectives and Conclusion

Cutaneous T-cell Lymphoma Analyst Views

Cutaneous T-cell Lymphoma Key Companies

Appendix

List of Tables
Table 1 Total Products for Cutaneous T-cell Lymphoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Cutaneous T-cell Lymphoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Soligenix
  • Elorac
  • 4SC AG
  • Merck Sharp & Dohme Corp.
  • Innate Pharma
  • Viridian Therapeutics
  • Sorrento Therapeutics
  • Bio-Path Holdings, Inc.
  • Legend Biotech USA Inc.
  • Genzada Pharmaceuticals
  • VidacPharma
  • Medc Biopharma
Note: Product cover images may vary from those shown
Adroll
adroll